Invitae Appointed to National Quality Forum Committee on Quality Standards for Healthcare
Invitae (NYSE: NVTA) has been appointed to a National Quality Forum (NQF) committee for a three-year term, marking it as the first genetics testing company to join this panel. The committee will focus on quality standards that influence healthcare delivery, with the goal of integrating genetics into mainstream medical practices. This move is anticipated to enhance healthcare quality and potentially improve outcomes for millions, particularly in areas like cancer and cardiovascular disease.
- Appointment to the NQF committee is a significant recognition of Invitae's role in genetics.
- This strategic involvement may lead to improved healthcare standards and practices.
- Potential to enhance healthcare equity and reduce disparities in patient outcomes.
- None.
– First genetics testing company to sit on Forum –
– Genetics perspective on committee will accelerate healthcare quality standards aligning with medical and technological advancements –
SAN FRANCISCO, Sept. 27, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the company has received a three-year appointment to a National Quality Forum (NQF) committee that provides input on recommendations for quality standards that impact how healthcare is delivered. Invitae is the first genetics testing company to join the Measure Applications Partnership (MAP) Clinician workgroup committee, representing a critical step in making genetics the standard of care in mainstream medicine and potentially improving healthcare for billions.
The MAP Clinician workgroup is a multi-stakeholder partnership with organizations such as health plans and provider organizations tasked with providing recommendations to the U.S. Department of Health and Human Services on the selection and removal of performance measures for federal public reporting, performance-based payment and other health programs.
"The selection of Invitae to the MAP Clinician workgroup indicates the National Quality Forum is prioritizing genomics for their work in setting standards for quality healthcare. I am glad to see NQF playing an active role to help incentivize this progress of medicine and applaud their choice of Invitae. I look forward to Invitae's contributions in this partnership," said Christine Cassel, MD, former NQF president and CEO and former planning dean for Kaiser Permanente's School of Medicine.
The MAP Clinician workgroup plays an important role for NQF's evaluation and endorsement process for implementation of standardized healthcare performance measures. Both public and private payers use measures for a variety of accountability purposes, including public reporting and performance-based payment programs. Measures are an essential part of making the quality and cost of healthcare more transparent to all, which is important for those who receive care or make care decisions for loved ones. Use of standardized healthcare performance measures allows for comparison across clinicians, hospitals, health plans and other providers.
"We believe healthcare quality, equity and patient safety cannot be addressed without the recognition that genetics plays a critical role. With this consideration, quality standards can help providers and health plans keep up with the evidence, clinical guidelines and advancement of medicine," said Chantelle Schenning, PhD, MHA, head of healthcare transformation at Invitae. "NQF's decision to invite our voice to represent the genetics perspective and expertise creates a more balanced, diverse stakeholder group that better aligns with advancements in clinical care seen in the outpatient setting today."
Each year, millions of people are screened for or diagnosed with diseases for which their genetic information can be clinically actionable for them and their families. As genetic information becomes increasingly important in driving healthcare decision-making and outcomes, quality standards should reflect and encourage the relevant use of genetics in clinical practice to help treat and prevent disease. If incorporated appropriately, the inclusion of genetics in quality measures could reduce (rather than widen) existing disparities in patient outcomes in cancer, cardiovascular disease, pediatrics and many others.
About the National Quality Forum
The National Quality Forum (NQF) works with members of the healthcare community to drive measurable health improvements together. NQF is a not-for-profit, membership-based organization that gives all healthcare stakeholders a voice in advancing quality measures and improvement strategies that lead to better outcomes and greater value. Learn more at www.qualityforum.org.
About Invitae
Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time and lower prices. For more information, visit the company's website at invitae.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's beliefs regarding its appointment to the NQF committee, including that it will accelerate healthcare quality standards aligning with medical and technological advancements and that it represents a critical step in making genetics the standard of care in mainstream medicine and potentially improving healthcare for billions; and the company's belief that the inclusion of genetics in quality measures could reduce existing disparities in patient outcomes in many diseases. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company's history of losses; the company's ability to compete; the company's failure to manage growth effectively; the company's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the company's ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to the company's business; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.
Contact:
Renee Kelley
pr@invitae.com
(628) 213-3283
View original content to download multimedia:https://www.prnewswire.com/news-releases/invitae-appointed-to-national-quality-forum-committee-on-quality-standards-for-healthcare-301633447.html
SOURCE Invitae Corporation
FAQ
What is Invitae's recent appointment related to the NQF?
What impact does Invitae's appointment have on healthcare standards?
How long is Invitae's term with the NQF committee?
Why is Invitae's role in the NQF committee important?
